Abstract
Purpose
The objective of this study was to measure the impact of an intervention on the prescription habits of general practitioners (GPs) in order to improve the quality of zolpidem prescriptions in patients aged 75 or older.
Methods
A prospective multicentric non-randomized trial was performed in the Metropolitan Granada Primary Healthcare Area (Andalusian Public Healthcare Service, Spain), which serves a total population of approximately 675,000 inhabitants. All health centers volunteering to participate in the trial were included. The intervention consisted of training sessions, individualized feedback, clinical information, and financial incentives. A daily dose over 5 mg was considered non-safe. Reduction in non-safe prescriptions of zolpidem in the elderly population became a quality prescribing indicator in a pay-for-performance scheme.
Results
Statistically significant differences versus baseline were found between the intervention and control groups in mean zolpidem prescription prevalence (28.5 vs. 37.5‰, respectively; p = 0.008) and mean non-safe zolpidem prescription prevalence (16.5 vs. 34.2‰, respectively; p < 0.001). At the end of the study period, the total number of non-safe prescriptions was 1309, 35% lower versus baseline, with a significant difference of p < 0.001; the number in the intervention (510 vs. 1118; p < 0.001) and control (799 vs. 893; p = 0.0064) groups was also significantly lower, with a significantly greater percentage reduction in the intervention group (54.4 vs. 10.5%, p < 0.001).
Conclusion
The quality prescribing indicator in our area was improved by the intervention developed. Further studies that include an intervention group of GPs who receive no financial incentive are required to evaluate the relative importance of an economic reward in achieving this improvement.
Similar content being viewed by others
References
Levy HB (2014) Non-benzodiazepine hypnotics and older adults: what are we learning about zolpidem? Expert Rev Clin Pharmacol 7:5–8. doi:10.1586/17512433.2014.864949
Sanger DJ (2004) The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18(Suppl 1):9–15
Vicente Sánchez MP, Macías Saint-Gerons D, de la Fuente HC et al Trends of use of anxiolytics and hypnotics in Spain from 2000 to 2011. Rev española salud pública 87:247–255. doi:10.4321/S1135-57272013000300004
Walsh JK, Soubrane C, Roth T (2008) Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 16:44–57. doi:10.1097/JGP.0b013e3181256b01
American Geriatrics Society (2015) 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 63. doi:10.1111/jgs.13702
Griebling TL (2012) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Urol 188:1211–1212. doi:10.1016/j.juro.2012.06.105
American Geriatrics Society (2013) Ten things physicians and patients should question. http://www.choosingwisely.org/societies/american-geriatrics-society/. Accessed 1 Dec 2015
Allain H, Bentué-Ferrer D, Polard E et al (2005) Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 22:749–765
Kajiwara A, Yamamura M, Murase M et al (2015) Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects. Aging Ment Health:1–5. doi:10.1080/13607863.2015.1031640
MacFarlane J, Morin CM, Montplaisir J (2014) Hypnotics in insomnia: the experience of zolpidem. Clin Ther 36:1676–1701. doi:10.1016/j.clinthera.2014.09.017
Garrido MM, Prigerson HG, Penrod JD et al (2014) Benzodiazepine and sedative-hypnotic use among older seriously ill veterans: choosing wisely? Clin Ther 36:1547–1554. doi:10.1016/j.clinthera.2014.10.007
U.S. Food and Drug Administration (2013) Safety alerts for human medical products—zolpidem containing products: drug safety communication—FDA requires lower recommended doses. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm334738.htm. Accessed 1 Dec 2015
Agencia Española de Medicamentos y Productos Sanitarios (2014) Notas informativas - Medicamentos de Uso Humano - Seguridad - 2014 - Zolpidem (Dalparan®, Stilnox®, Zolpidem EFG®): riesgo de somnolencia al día siguiente. http://www.aemps.gob.es/informa /notasInformativas/medicamentosUsoHumano/seguridad/2014/NI-MUH_FV_05-2014-zolpidem.htm. Accessed 1 Dec 2015
European Medicines Agency (2014) New advice to minimise risk of next-morning impaired driving ability and mental alertness with zolpidem. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zolpidem-containing_medicinal_products/European_Commission_final_decision/WC500170560.pdf. Accessed 1 Dec 2015
WHO (2015) Rational use of medicines. In: WHO. http://www.who.int/medicines/areas/rational_use/en/. Accessed 5 Oct 2016
Pimlott NJG, Hux JE, Wilson LM et al (2003) Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. CMAJ 168:835–839
Fernández Urrusuno R, Montero Balosa MC, Pérez Pérez P, Pascual de la Pisa B (2013) Compliance with quality prescribing indicators in terms of their relationship to financial incentives. Eur J Clin Pharmacol 69:1845–1853. doi:10.1007/s00228-013-1542-4
Fernández Urrusuno R, Pérez Pérez P, Montero Balosa MC et al (2014) Compliance with quality prescribing indicators linked to financial incentives: what about not incentivized indicators?: an observational study. Eur J Clin Pharmacol 70:303–311. doi:10.1007/s00228-013-1610-9
Ahuja V, Sohn M-W, Birge JR et al (2015) Geographic variation in rosiglitazone use surrounding FDA warnings in the Department of Veterans Affairs. J Manag care Spec Pharm 21:1214–1234. doi:10.18553/jmcp.2015.21.12.1214
Leal I, Romio SA, Schuemie M et al (2013) Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol 75:861–868. doi:10.1111/j.1365-2125.2012.04401.x
Ruiter R, Visser LE, van Herk-Sukel MPP et al (2012) Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Drug Saf 35:471–480. doi:10.2165/11596950-000000000-00000
Harward JL, Clinard VB, Jiroutek MR et al (2015) Impact of a US Food and Drug Administration drug safety communication on zolpidem dosing: an observational retrospective cohort. Prim care companion CNS Disord. doi:10.4088/PCC.14m01728
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical standards
The manuscript does not contain clinical studies or patient data.
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
ESM 1
(DOCX 33 kb)
Rights and permissions
About this article
Cite this article
López-Sepúlveda, R., García Lirola, M.Á., Espínola García, E. et al. Effects of a primary care intervention to improve the quality of zolpidem prescriptions in elderly patients. Eur J Clin Pharmacol 73, 455–461 (2017). https://doi.org/10.1007/s00228-016-2180-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-016-2180-4